AOXG logo

Aoxing Pharmaceutical Company, Inc. (AOXG) Aktienanalyse

Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Aoxing Pharmaceutical Company, Inc. (AOXG) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Bewertet mit 49/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.

Zuletzt analysiert: 17. März 2026
49/100 KI-Bewertung

Aoxing Pharmaceutical Company, Inc. (AOXG) Gesundheitswesen & Pipeline-Uebersicht

CEOZhenjiang Yue
Mitarbeiter346
HauptsitzShijiazhuang, CN
IPO-Jahr2005

Aoxing Pharmaceutical Company, Inc. is a specialty pharmaceutical company based in China, focusing on narcotic, pain-management, and addiction treatment products, including both herbal and synthetic drugs. With a negative P/E ratio and high gross margin, the company navigates a competitive landscape while developing new pain and addiction treatments.

Datenherkunft | Finanzdaten Quantitative Analyse NASDAQ Analyse: 17. März 2026

Investmentthese

Aoxing Pharmaceutical Company, Inc. presents a high-risk, high-reward investment profile. The company's focus on the Chinese market for pain management and addiction treatment offers potential growth, especially with its pipeline of drugs like Oxycodone/Acetaminophen and Buprenorphine/Naloxone. However, the company's negative P/E ratio of -183.91 and a negative profit margin of -79.5% raise concerns about its financial stability. Successful navigation of clinical trials and regulatory approvals for its pipeline drugs are key catalysts. Investors should closely monitor the company's progress in these areas, as well as its ability to improve profitability and manage its high beta of -59.16.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

  • Market Cap of $0.00B indicates a micro-cap company with limited resources and higher volatility.
  • P/E Ratio of -183.91 reflects the company's current unprofitability, requiring careful evaluation of future earnings potential.
  • Gross Margin of 88.1% suggests strong pricing power on existing products, but this needs to translate into overall profitability.
  • Beta of -59.16 indicates an inverse correlation with the market, which is unusual and may be due to the stock's illiquidity or unique business model.
  • Focus on narcotic, pain-management, and addiction treatment pharmaceutical products in China, a market with significant unmet needs and growth potential.

Wettbewerber & Vergleichsunternehmen

Staerken

  • Specialized focus on pain management and addiction treatment.
  • Established manufacturing capabilities in China.
  • Pipeline of drugs in development.
  • Existing distribution network within China.

Schwaechen

  • Negative profitability and high debt levels.
  • Reliance on a single geographic market (China).
  • Limited financial resources for R&D and marketing.
  • OTC Other tier indicates higher risk.

Katalysatoren

  • Upcoming: Regulatory approval and commercialization of Oxycodone and Acetaminophen tablets and capsules for pain management.
  • Upcoming: Positive results from Phase III clinical trials for Buprenorphine/Naloxone in treating opioid dependence.
  • Ongoing: Expansion of distribution network within China to reach more patients.
  • Ongoing: Increased government support for domestic pharmaceutical companies in China.
  • Ongoing: Growing demand for pain management and addiction treatment products in China.

Risiken

  • Potential: Failure to obtain regulatory approvals for pipeline drugs.
  • Potential: Intense competition from established pharmaceutical companies.
  • Ongoing: Pricing pressures from generic drug manufacturers.
  • Ongoing: Dependence on the Chinese market and regulatory environment.
  • Potential: Product liability claims and lawsuits.

Wachstumschancen

  • Expansion of Product Portfolio: Aoxing's pipeline of drugs in development, including Oxycodone/Acetaminophen and Buprenorphine/Naloxone, represents a significant growth opportunity. Successful completion of clinical trials and regulatory approvals could lead to new revenue streams and market share gains. The market for pain management and addiction treatment is substantial, with the global market estimated to reach billions of dollars in the coming years. Timeline: 2-5 years for regulatory approvals.
  • Geographic Expansion within China: While Aoxing primarily operates in China, there is potential to expand its geographic reach within the country. Targeting specific regions with high demand for pain management and addiction treatment products could drive revenue growth. This expansion could involve establishing new distribution channels and partnerships. Timeline: 1-3 years.
  • Strategic Partnerships and Acquisitions: Aoxing could pursue strategic partnerships or acquisitions to expand its product portfolio, geographic reach, or technological capabilities. Collaborating with other pharmaceutical companies or research institutions could accelerate the development and commercialization of new drugs. Timeline: Ongoing.
  • Increased Investment in Research and Development: Aoxing could increase its investment in research and development to discover and develop novel drugs for pain management and addiction treatment. This could involve conducting preclinical and clinical studies, as well as collaborating with academic institutions and research organizations. Timeline: Long-term, 5+ years.
  • Leveraging Government Support for Domestic Pharmaceutical Companies: The Chinese government is actively supporting the growth of domestic pharmaceutical companies through various policies and initiatives. Aoxing can leverage these policies to access funding, streamline regulatory approvals, and gain a competitive advantage. Timeline: Ongoing.

Chancen

  • Expanding into new geographic markets.
  • Developing new drug formulations and delivery methods.
  • Partnering with other pharmaceutical companies.
  • Leveraging government support for domestic pharmaceutical companies.

Risiken

  • Intense competition from established pharmaceutical companies.
  • Stringent regulatory requirements.
  • Pricing pressures from generic drug manufacturers.
  • Potential product liability claims.

Wettbewerbsvorteile

  • Proprietary drug formulations and intellectual property.
  • Established distribution network within China.
  • Expertise in developing and manufacturing narcotic and pain-relief medications.
  • Regulatory approvals for its existing products.

Ueber AOXG

Aoxing Pharmaceutical Company, Inc., headquartered in Shijiazhuang, China, is a specialty pharmaceutical company dedicated to the research, development, manufacture, and distribution of pharmaceutical products. The company primarily operates in the People's Republic of China, focusing on narcotic, pain-management, and addiction treatment medications. Aoxing’s product portfolio includes Zhongtong'an, a herbal capsule designed for oral and dental pain relief, and Yiqi Qiangshen Granule, an over-the-counter herbal supplement aimed at tonifying qi, empowering the body, and promoting blood circulation. Additionally, the company manufactures Tilidine hydrochloride, a synthetic narcotic analgesic tablet used for moderate to severe pain relief. Further expanding their offerings, Aoxing has several products in development, including Oxycodone and Acetaminophen tablets and capsules, which have completed clinical trials for treating acute and chronic pain. They are also developing Buprenorphine/Naloxone, a sublingual tablet for opioid dependence treatment, which has completed Phase II clinical trials, and Tilidine/Naloxone, a compound capsule in Phase II clinical trials for acute and chronic pain management. Originally known as China Aoxing Pharmaceutical Company, Inc., the company rebranded to Aoxing Pharmaceutical Company, Inc. in March 2010, solidifying its commitment to advancing pharmaceutical solutions.

Was das Unternehmen tut

  • Researches and develops pharmaceutical products focused on pain management, addiction treatment, and related areas.
  • Manufactures narcotic and non-narcotic pain relief medications.
  • Produces herbal extraction products for pain relief and general health improvement.
  • Distributes its pharmaceutical products primarily within the People's Republic of China.
  • Conducts clinical trials for new drug candidates, including treatments for opioid dependence.
  • Markets both prescription and over-the-counter (OTC) medications.

Geschaeftsmodell

  • Develops and manufactures pharmaceutical products.
  • Sells prescription and OTC medications through distributors and directly to healthcare providers.
  • Generates revenue from the sale of its proprietary drug formulations.
  • Invests in research and development to create new products and improve existing ones.

Branchenkontext

Aoxing Pharmaceutical Company, Inc. operates within the specialty and generic drug manufacturing industry, a sector characterized by intense competition and stringent regulatory oversight. The Chinese pharmaceutical market is experiencing rapid growth, driven by an aging population and increasing healthcare spending. However, domestic companies face challenges from international players and evolving regulatory standards. Aoxing's focus on pain management and addiction treatment positions it in a niche market with specific needs, but also heightened regulatory scrutiny. Competitors like AREVF and CWWBF also operate in this space.

Wichtige Kunden

  • Hospitals and clinics throughout China.
  • Pharmacies and drug stores.
  • Patients seeking pain relief and addiction treatment.
  • Healthcare providers prescribing medications.
KI-Zuversicht: 69% Aktualisiert: 17. März 2026

Finanzdaten

Chart & Info

Aoxing Pharmaceutical Company, Inc. (AOXG) Aktienkurs: Price data unavailable

Aktuelle Nachrichten

Keine aktuellen Nachrichten fuer AOXG verfuegbar.

Analystenkonsens

Konsens-Bewertung

Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer AOXG.

Kursziele

Wall-Street-Kurszielanalyse fuer AOXG.

MoonshotScore

49/100

Was bedeutet diese Bewertung?

Der MoonshotScore bewertet das Wachstumspotenzial von AOXG auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.

Fuehrung: Zhenjiang Yue

CEO

Zhenjiang Yue serves as the CEO of Aoxing Pharmaceutical Company, Inc. He is responsible for overseeing the company's overall strategy, operations, and financial performance. His leadership is crucial in guiding Aoxing through the complex regulatory landscape and competitive market in China. He manages a workforce of 346 employees, focusing on research, development, and manufacturing of pharmaceutical products.

Erfolgsbilanz: Under Zhenjiang Yue's leadership, Aoxing Pharmaceutical Company has focused on developing and commercializing pain management and addiction treatment products. Key milestones include advancing clinical trials for pipeline drugs such as Oxycodone/Acetaminophen and Buprenorphine/Naloxone. The company has also maintained its presence in the Chinese pharmaceutical market despite financial challenges.

AOXG OTC-Marktinformationen

The OTC Other tier represents the lowest tier of the OTC market, indicating that Aoxing Pharmaceutical Company, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and viability. Investing in OTC Other stocks carries significantly higher risk compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.

  • OTC-Stufe: OTC Other
  • Offenlegungsstatus: Unknown
Liquiditaet: Liquidity in OTC Other stocks is typically very low, with wide bid-ask spreads and limited trading volume. This can make it difficult for investors to buy or sell shares without significantly impacting the price. The low liquidity also increases the risk of price manipulation and makes it challenging to establish a fair market value for the stock. Investors should be prepared for potential delays in executing trades and significant price volatility.
OTC-Risikofaktoren:
  • Limited financial disclosure and transparency.
  • Low trading volume and liquidity.
  • Higher risk of fraud and manipulation.
  • Potential for delisting or suspension of trading.
  • Limited regulatory oversight.
Sorgfaltspruefung-Checkliste:
  • Verify the company's registration and legal status.
  • Obtain and review any available financial statements.
  • Assess the company's business model and competitive landscape.
  • Evaluate the management team's experience and track record.
  • Understand the risks associated with investing in OTC Other stocks.
  • Consult with a qualified financial advisor.
  • Check for any regulatory actions or legal disputes.
Legitimitaetssignale:
  • Existence of a physical headquarters and operational facilities.
  • Presence of a functional website and contact information.
  • Patents or intellectual property related to its products.
  • Partnerships with reputable organizations or institutions.
  • Active engagement with investors and the public.

Was Anleger ueber Aoxing Pharmaceutical Company, Inc. (AOXG) wissen wollen

What are the key factors to evaluate for AOXG?

Aoxing Pharmaceutical Company, Inc. (AOXG) currently holds an AI score of 49/100, indicating low score. Key strength: Specialized focus on pain management and addiction treatment.. Primary risk to monitor: Potential: Failure to obtain regulatory approvals for pipeline drugs.. This is not financial advice.

How frequently does AOXG data refresh on this page?

AOXG prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven AOXG's recent stock price performance?

Recent price movement in Aoxing Pharmaceutical Company, Inc. (AOXG) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized focus on pain management and addiction treatment.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider AOXG overvalued or undervalued right now?

Determining whether Aoxing Pharmaceutical Company, Inc. (AOXG) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying AOXG?

Before investing in Aoxing Pharmaceutical Company, Inc. (AOXG), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding AOXG to a portfolio?

Potential reasons to consider Aoxing Pharmaceutical Company, Inc. (AOXG) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Specialized focus on pain management and addiction treatment.. Additionally: Established manufacturing capabilities in China.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.

Can I buy fractional shares of AOXG?

Yes, most major brokerages offer fractional shares of Aoxing Pharmaceutical Company, Inc. (AOXG) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track AOXG's earnings and financial reports?

Aoxing Pharmaceutical Company, Inc. (AOXG) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for AOXG earnings announcements is recommended.

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Analyse aktualisiert am KI-Bewertung taeglich aktualisiert
Datenquellen & Methodik
Marktdaten bereitgestellt von Financial Modeling Prep & Yahoo Finance. KI-Analyse durch proprietaere Algorithmen von Stock Expert AI. Technische Indikatoren nach branchenueblichen Berechnungsstandards. Zuletzt aktualisiert: .

Daten dienen ausschliesslich zu Informationszwecken.

Analysehinweise
  • Information is based on available data as of 2026-03-17.
  • OTC Other stocks carry significant risks and require thorough due diligence.
  • Financial data may be limited or unaudited.
Datenquellen

Popular Stocks